Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Graham Skellern 15 Jan 2025
Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

Staff reporters 15 Jan 2025
Cross-border rules on aviation emissions give airlines easy ride
Markets

Cross-border rules on aviation emissions give airlines easy ride

Around 80% of Air NZ's emissions from jet fuel are from international flights.

Greg Hurrell 15 Jan 2025
Analysts expect RV companies to raise equity
Property

Analysts expect RV companies to raise equity

“We expect investor support for a capital raise," Jarden's Arie Dekker said.

Gregor Thompson 15 Jan 2025